Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Phase of Trial: Phase IV
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Perampanel (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions
- Acronyms FYC02T
- Sponsors Eisai Co Ltd
- 04 Feb 2019 Planned End Date changed from 1 Feb 2022 to 27 Feb 2021.
- 04 Feb 2019 Planned primary completion date changed from 1 Feb 2022 to 27 Feb 2021.
- 21 Aug 2018 Planned End Date changed from 1 Feb 2023 to 1 Feb 2022.